Hemoglobin is associated with cardiotoxicity in melanoma patients without anemia receiving immune checkpoint inhibitor therapy
Hemoglobin values within the normal limits are associated with cardiovascular toxicity in terms of CTRCD in this cohort of melanoma patients receiving ICI treatment. Future studies are needed to investigate underlying mechanisms and validate the clinical utility of hemoglobin as a potential additional biomarker for risk stratification in cancer patients.
Authors
- Elias Haj‐Yehia (ORCID: https://orcid.org/0000-0002-6602-7025)
- Phillip Schulte
- Raluca Mincu (ORCID: https://orcid.org/0000-0002-9032-2630)
- Amir Abbas Mahabadi (ORCID: https://orcid.org/0000-0003-2336-7991)
- Tienush Rassaf (ORCID: https://orcid.org/0000-0001-8001-0265)
- Sebastian Korste (ORCID: https://orcid.org/0000-0001-5834-447X)
- Matthias Totzeck (ORCID: https://orcid.org/0000-0001-7898-3906)
- Lars Michel
- Samuel Dautzenberg
Institutions
- Essen University Hospital (DE)
- West German Heart and Vascular Center Essen (DE)
Publication Details
- Journal
- IJC Heart & Vasculature
- Published
- 2025-05-08
- DOI
- https://doi.org/10.1016/j.ijcha.2025.101693
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00